Cytokinetics Inc.
NASDAQ · CYTK·South San Francisco, CA·Large-cap·Approved
Muscle biology company with aficamten approved for obstructive hypertrophic cardiomyopathy (oHCM). Cytokinetics' cardiac myosin platform also yielded omecamtiv mecarbil (partnered with Roche) for heart failure, with additional programs targeting skeletal muscle disorders.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Cytokinetics Corporate Overview 2025 | Corporate overview | October 1, 2025 | 2 |